You are here

Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease

Baxter International Inc. announced that its Phase III clinical study of immunoglobulin (IG) did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease.

CLICK HERE to read the full article.

News Category: